2129. Virologic and Immunologic Outcomes in HIV-infected Patients with Non-AIDS-Defining and AIDS-Defining Cancers
Session: Poster Abstract Session: HIV: Cancers, HPV, Dysplasia
Saturday, October 29, 2016
Room: Poster Hall
Posters
  • Poster pdf.pdf (216.8 kB)
  • Background:

    To compare the virologic and immunologic outcomes between HIV-infected patients with non-AIDS-defining cancers (NADC) and those with AIDS-defining cancers (ADC).

    Methods:

    All HIV-infected patients with a diagnosis of cancer between 2000 and 2011 were included for review. HIV-related outcomes (HIV-1 RNA viral load and CD4 cell count) were abstracted and compared for patients with NADCs and ADCs.

    Results:

    412 patients with baseline CD4 or HIV-1 RNA viral load data were analyzed. There were 122 (30%) diagnoses of ADCs and 290 (70%) NADCs. Patients with NADCs had a higher median age (54 years vs. 43 years, p<0.0001) and a higher frequency of hepatitis C co-infection (52% vs. 36%, p=0.002). The median baseline CD4 was lower for patients with ADCs (137 cells/mm3 vs. 314 cells/mm3) and patients with NADCs were more likely to be suppressed at cancer diagnosis (59% vs. 25%, p<0.0001). The median CD4 for patients with NADCs was significantly higher than patients with ADCs at 6 and 12 months after diagnosis, and higher at 18 and 24 months but not significantly. Patients with an NADC had 2.19 times (95%CI 1.04-4.62) the adjusted odds of being suppressed at 12 months and 2.17 times the odds (95%CI 0.92-5.16) at 24 months compared to patients with an ADC diagnosis.

    Conclusion:

    For patients diagnosed with ADCs and NADCs in this urban clinic setting, both virologic suppression and immunologic recovery improved over time. Patients with NADCs had the highest odds of virologic suppression in the 2 years following cancer diagnosis.

    Figure. Proportion of cases with virologic suppression ≤400 copies/ml after cancer diagnosis.

     

    David J. Riedel, M.D., M.P.H., Infectious Disease, Institute of Human Virology and University of Maryland School of Medicine, Baltimore, MD, Kristen Stafford, PhD, MPH, Epidemiology and Public Health, Institute of Human Virology of the University of Maryland School of Medicine, Baltimore, MD, Aparna Vadlamani, MPH, University of Maryland School of Medicine, Baltimore, MD and Robert R. Redfield, MD, Institute of Human Virology and University of Maryland School of Medicine, Baltimore, MD

    Disclosures:

    D. J. Riedel, None

    K. Stafford, None

    A. Vadlamani, None

    R. R. Redfield, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.